
GSK Korea's long-acting HIV injection therapy gains insurance benefit
GSK Korea said its long-acting injectable HIV-1 combination treatment, Vocabria (ingredient: cabotegravir 600mg) and Rekambys (ingredient: rilpivirine 900mg), began to be covered by Korea’s national health insurance system on Tuesday. This marks a …